Cyxone has decided to apply for a listing of its share on Nasdaq Stockholm Main Market
Cyxone (publ.) announced today that its Board of Directors has decided to apply for a listing of the company’s share on Nasdaq Stockholm Main Market. The company will prepare to submit an application in the first quarter of 2022. Cyxone is currently listed on Nasdaq First North Growth Market.Cyxone develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Its most advanced project, Rabeximod, is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis